Abstracts Archive - Page 1437 of 2607 - ACR Meeting Abstracts

Abstract Number: 746 • 2017 ACR/ARHP Annual Meeting
Comparison of Disease Characteristics in Patients with Juvenile-Onset and Adult-Onset Progressive Systemic Sclerosis
Guzin Karatemiz¹, Amra Adrovic², Sinem Nihal Esatoglu¹, Sezgin Sahin², Kenan Barut², Gulen Hatemi¹, Vedat Hamuryudan¹, Ozgur Kasapcopur² and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Pediatric Rheumatology, Istanbul University, Cerrahpasa Medical School, Department of Pediatric Rheumatology, Istanbul, Turkey
Background/Purpose: Progressive systemic sclerosis (PSSc) has been known to affect mainly adults of 30-50 years of age. Juvenile –onset has been reported to be rare…
Abstract Number: 747 • 2017 ACR/ARHP Annual Meeting
Autoantibodies to Rpp25 (Th/To) Are Specific Markers for Systemic Sclerosis and Are Associated with Limited Cutaneous Disease and Young Age at Disease Onset
Boyang Zheng¹, Martial Koenig², Marychel Tiongson³, Andrea Seaman³, Danilo Villalta⁴, Gabriella Morozzi⁵, Nicola Bizzaro⁶, Gabriella Pucci⁷, Michaelin Richards³ and Michael Mahler³, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, ²Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada, ³Research and Development, Inova Diagnostics, San Diego, CA, ⁴Allergologia e Immunologia Clinica, AO S. Maria degli Angeli, Pordenone, Pordenone, Italy, ⁵Chirurgiche e Neuroscienze, Sezione di Reumatologia, Università di Siena, Dipartimento Scienze Mediche, Siena, Italy, ⁶Ospedale San Antonio, Tolmezzo, Italy, ⁷Chirurgiche e Neuroscienze, Sezione di Reumatologia, Università di Siena, Siena, Italy
Autoantibodies to Rpp25 (Th/To) are specific markers for systemic sclerosis and are associated with limited cutaneous disease and young age at disease onset[MM1] Boyang Zheng4, Martial…
Abstract Number: 748 • 2017 ACR/ARHP Annual Meeting
Scleromyxedema Phenotype Pre- and Post-Treatment with Intravenous Immunoglobulin
Christopher A. Mecoli¹, Andrea Fava², Francesco Boin³ and Laura K. Hummers⁴, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Rheumatology, University California, San Francisco, San Francisco, CA, ⁴Medical and Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: Scleromyxedema is a rare scleroderma mimic that often responds to intravenous immunoglobulin therapy (IVIG). The clinical and biochemical changes in response to treatment have…
Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
Abstract Number: 750 • 2017 ACR/ARHP Annual Meeting
Diltiazem Gel As a New Local Treatment for Scleroderma Digital Ulcers
Mohammad Ali Nazarinia¹, Elmira Esmaeilzadeh² and Saeedeh Shenavandeh², ¹Shiraz Geriatric Research Center, Shiraz University of Medical Sciences, Shiraz, Iran, Shiraz, Iran (Islamic Republic of), ²Department of Internal Medicine, Division of Rheumatology, Shiraz University of Medical Sciences, Shiraz, Iran., Shiraz, Iran (Islamic Republic of)
Background/Purpose: Assessing the effect of Diltiazem gel on healing process of scleroderma digital ulcers and comparing its effect with Nitroglycerin ointment and placebo. Methods: Ninety…
Abstract Number: 751 • 2017 ACR/ARHP Annual Meeting
Effect of Probiotics on the Gastrointestinal Symptoms and Immune Parameters in Patients with Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Thais Marighela¹, Maria Izabel Arismendi¹, Milena Brunialti² and Cristiane Kayser¹, ¹Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ²Division of Infectious Diseases, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: Abnormalities in the intestinal microbiota have been associated with several autoimmune diseases, including systemic sclerosis (SSc). Recent studies have demonstrated the potential of probiotics…
Abstract Number: 752 • 2017 ACR/ARHP Annual Meeting
Role of the Six-Minute Walk Test in Systemic Sclerosis: Five Years Evolution
Els Vandecasteele¹, Karin Melsens², Filip De Keyser³, Michel De Pauw⁴, Ellen Deschepper⁵, Saskia Decuman⁶, Yves Piette², Kristof Thevissen⁷, Guy Brusselle⁸ and Vanessa Smith³, ¹Dep of Cardiology, University Hospital Ghent, Ghent, Belgium, ²Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, Ghent, Belgium, ³Ghent University, Department of Internal Medicine, Ghent, Belgium, Ghent, Belgium, ⁴Dep of cardiology, University Hospital Ghent, Ghent, Belgium, ⁵Biostatistics Unit, UGent, Ghent, Belgium, ⁶Department of Internal Medicine, Ghent University, Ghent, Belgium, ⁷University Hospital Ghent, Ghent, Belgium, ⁸Gent University, Gent, Belgium
TitleRole of the Six-Minute Walk Test in Systemic Sclerosis: five years evolution. Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading…
Abstract Number: 753 • 2017 ACR/ARHP Annual Meeting
The Histone Demethylase Jumonji Domain-Containing Protein 3 (JMJD3) As Central Mediator of Fibroblast Activation
Christina Bergmann¹, Amelie Brandt¹, Clara Dees², Yun Zhang³, Chih-Wei Chen⁴, Tatjana Mallano⁵, Thomas Wohlfahrt⁶, Ruifang Liang⁷, Rosebeth Kagwiria¹, Aline Bozec⁸, Ralf Rieker⁹, David Abraham¹⁰, Andreas Ramming¹¹, Oliver Distler¹², Georg Schett¹³ and Jörg Distler¹⁴, ¹Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology,, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3 and Institute for Clinical Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁸Department Clinic of Medicine 3 - Immunology und Rheumatology, University of Erlangen-Nürnberg, Department Clinic of Medicine 3 - Immunology and Rheumatology, Erlangen, Germany, Erlangen, Germany, ⁹Department of Pathology, University Clinic Erlangen, Erlangen, Germany, ¹⁰Centre for Rheumatology and Connective Tissue, UCL School of Life and Medical Sciences, London, London, United Kingdom, ¹¹Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ¹²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹³Department of Internal Medicine 3 – Rheumatology and Immunology, Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University of Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ¹⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Epigenetic modifications are key drivers of chronic fibroblast activation. Trimethylation of histone 3 at lysine residue K27 (H3K27me3) is a repressive modification, that is…
Abstract Number: 754 • 2017 ACR/ARHP Annual Meeting
Interferon Siganture in Systemic Sclerosis Lung Microvascular Endothelial Cells
Fabian A Mendoza¹, Sonsoles Piera-Velazquez², Peter J. Wermuth³, Sankar Addya⁴, Carol A. Feghali-Bostwick⁵ and Sergio A. Jimenez⁶, ¹Rheumatology Division, Department of Medicine, Thomas Jefferson University, Jefferson Institute of Molecular Medicine and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ²Jefferson Institute of Molecular Medicine and Scleroderma Center., Thomas Jefferson University, Philadelphia, PA, ³Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA, ⁴Kimmel Cancer Center, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, ⁵Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁶Scleroderma Center and Jefferson Institute of Molecular Medicine, Thomas Jefferson Univ, Philadelphia, PA
Background/Purpose: Systemic Sclerosis (SSc) is characterized by severe fibroproliferative vasculopathy, exaggerated deposition of extracellular matrix molecules (ECM) in skin and multiple internal organs, and alterations…
Abstract Number: 755 • 2017 ACR/ARHP Annual Meeting
Genome-Wide DNA Methylation Pattern in Systemic Sclerosis Microvascular Endothelial Cells: Identification of Epigenetically Affected Key Genes and Pathways
Shadia Nada¹, Ibtissam Gad², Ali Alqahtani³, Ahmad Assaly², Sadik Khuder⁴, Yongqing Wang⁵, Bashar Kahaleh¹ and Nezam Altorok¹, ¹Medicine/Rheumatology, University of Toledo, Toledo, OH, ²University of Toledo, Toledo, OH, ³Internal Medicine, University of Toledo, Toledo, OH, ⁴Department of Medicine, University of Toledo, Toledo, OH, ⁵Medicine, University of Toledo, Toledo, OH
Background/Purpose: The etiology of systemic sclerosis (SSc) is not clear, but there is evidence suggesting a critical role for epigenetic alterations in disease pathogenesis and…
Abstract Number: 756 • 2017 ACR/ARHP Annual Meeting
Novel Machine Learning Classifier Accurately Predicts Intrinsic Molecular Subsets for Patients with Systemic Sclerosis
Jennifer Franks¹, Viktor Martyanov¹, Guoshuai Cai¹ and Michael L. Whitfield², ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: High-throughput gene expression profiling of skin biopsies from patients with systemic sclerosis (SSc) has identified four “intrinsic” gene expression subsets conserved across multiple cohorts…
Abstract Number: 757 • 2017 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells Activated through TLR8 Promote Systemic Sclerosis
Marie-Dominique Ah Kioon¹, Claudio Tripodo², Alexandra Morquette³, Robert F. Spiera³, Jessica K. Gordon³ and Franck J. Barrat¹, ¹Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, ²Department of Health Science, Human Pathology, tumor immunology unit, Palermo, Italy, ³Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Plasmacytoid Dendritic Cells (PDCs) are the key cell type mediating TLR-induced inflammation in several autoimmune diseases such as lupus, dermatomyositis, lichen sclerosus and cutaneous…
Abstract Number: 758 • 2017 ACR/ARHP Annual Meeting
Identification of Biomarkers Predictive of Pulmonary Arterial Hypertension in Systemic Sclerosis
Kathleen D. Kolstad¹, Tyson Holmes², Yael Rosenberg-Hasson², Andrew Sweatt³, Roham T. Zamanian⁴, Shufeng Li⁵, Virginia D. Steen⁶, Paul J. Utz⁷ and Lorinda Chung⁸, ¹Rheumatology, Stanford University Medical Center, Stanford, CA, ²Stanford University Medical Center, Stanford, CA, ³Medicine, Division of Pulmonary and Critical Care, Stanford University Medical Center, Stanford, CA, ⁴Stanford University Medical Center, Palo Alto, CA, ⁵Dermatology, Stanford University School of Medicine, Stanford, CA, ⁶Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁷Medicine, Stanford University School of Medicine, Stanford, CA, ⁸Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by vascular abnormalities, immune system dysregulation, and fibrosis. Pulmonary arterial hypertension (PAH) affects approximately 10% of…
Abstract Number: 759 • 2017 ACR/ARHP Annual Meeting
Multi Dimensional Analysis of the Immunome in Systemic Sclerosis Reveals Functionally Related Abnormalities in MAIT and B Cell Compartments
Bhairav Paleja¹, Pavanish Kumar¹, Suzan Saidin¹, Ahmad Lajam², Camillus Chua¹, Liyun Lai¹, Andrea Hsiu Ling Low² and Salvatore Albani¹, ¹SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterised by excessive fibrosis of skin and internal organs, and vascular dysfunction. Association of T and B…
Abstract Number: 760 • 2017 ACR/ARHP Annual Meeting
Antisense Long Noncoding RNA HAND2-AS1 and OTUD6B-AS1 Have Important Roles in the Pathogenesis of Systemic Sclerosis
Miki Takata¹, Elena Pachera¹, Anastasiia Kozlova¹, Astrid Jüngel¹, Tobias Messemaker², Jeska de Vries-Bouwstra², Tom W.J. Huizinga³, Fina Kurreeman² and Oliver Distler⁴, ¹Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Leiden, Netherlands, ³Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁴Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Long noncoding RNAs (lncRNAs) represent a class of transcripts longer than 200 nucleotides that are not translated into proteins. In recent years, antisense (AS)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].